ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.
Also NCI prostate SPOREs plan biospecimen bank.
NCI advisors seek comment on clinical trials system, until Jan. 15.
NCI funds 17 EDRN biomarker labs. Bush signs omnibus funding legislation.
Dept. of Defense opens program announcements for prostate cancer research.
Children’s Cancer Research Institute at UT Health Science Center recruits faculty.
Two cancer center directors named: Michael Kastan at St. Jude, James Willson at Harold Simmons.
December issue of Business & Regulatory Report included (an additional 8 pages of industry news).
Next issue of The Cancer Letter is scheduled for Jan. 7, 2005.
Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- CBER Director Vinay Prasad dared to “say no to drugs”
- At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.” - Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
